Company / Operating Income
Rapport Therapeutics, Inc. Operating Income History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$83.1M
FY2024
5-year range
-$83.1M / -$36.2M
FY2023-FY2024
Trend
-129.6%
vs FY2023
Sector context
#84 of 204
Health Care
What the data says
At -$83M, Rapport Therapeutics, Inc.'s operating income ranks #84 of 204 in the Health Care sector.
Based on SEC 10-K filings.
-$83M in FY2024.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#84 of 204 in Health CareTop 41% of 204This company -$83.1M Sector average $107.7M
▼
-177.1% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 129.6% year-over-year.
- Ranks #84 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$83.1M | -129.6% |
| FY2023 | -$36.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026